


## Liberia

### Region: West Africa

#### Key information on co-financing

- Gross National Income per capita (2017): \$ 380
- Co-financing status (2019): Initial self-financing
- Country is projected to stay in initial self financing phase for next 5 years.




#### Immunisation financing

	2013	2014	2015	2016	2017
<b>Vaccines used in routine immunisation</b>					
- Government expenditure	\$ 120,132	\$ 232,500	\$ -	\$ 296,050	\$ 180,500
- Total expenditure	\$ 2,564,374	\$ 4,329,252	\$ 2,417,299	\$ 4,857,090	\$ 2,539,944
- Government as % of total	5%	5%	0%	6%	7%
<b>Routine immunisation</b>					
- Government expenditure	\$ 406,012	\$ 265,591	\$ 512,264	\$ 758,936	\$ 858,500
- Total expenditure	\$ 3,090,518	\$ 4,520,173	\$ 3,729,276	\$ 5,378,936	\$ 5,708,444
- Government as % of total	13%	6%	14%	14%	15%

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: **0.3%**

#### Expenditure on routine immunisation in 2017



Source: WHO National Health Accounts, 2015

#### Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Yellow Fever	Routine	2001-present	Yes
Pentavalent	Routine	2008-present	Yes
PCV	Routine	2014-present	Yes
HPV	Demonstration	2016	No
IPV	Routine	2016 introduction	No
Rotavirus	Routine	2016 introduction	Yes
Measles	Campaign	2018	No

#### Co-financing payments


Year	Total amount paid by the country	Co-financed vaccines		
		Vaccine	Type	Amount
2008	\$ 118,000	Penta	Yellow Fever	-
2009	\$ 182,000	Penta	Yellow Fever	-
2010	\$ 121,000	Penta	Yellow Fever	-
2011	\$ 166,000	Penta	Yellow Fever	-
2012	\$ 166,000	Penta	Yellow Fever	-
2013	\$ 143,000	Penta	Yellow Fever	-
2014	\$ 234,000	Penta	Yellow Fever	PCV
2015	*	Penta	Yellow Fever	PCV
2016	\$ 296,000	Penta	Yellow Fever	PCV
2017	\$ 195,000	Penta	Yellow Fever	PCV
2018	\$ 361,000	Penta	Yellow Fever	PCV

Note: Country co-financing was waived in 2015 due to Ebola.

## Co-financing obligations for 2019

	Co-financing obligations (in US\$)	Co-financing obligations (in doses)
PCV	\$ 91,500	30,800
YF	\$ 50,000	40,700
Pentavalent	\$ 130,000	182,500
Rota	\$ 57,500	25,500
HPV	\$ 27,000	5,900
Measles	\$ 62,000	187,800
<b>Total</b>	<b>\$ 418,000</b>	

## Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
HPV national	\$ 21,055	\$ 11,802	\$ 15,164	\$ 8,239	\$ 8,593
Penta	\$ 80,666	\$ 83,844	\$ 86,453	\$ 89,105	\$ 91,794
PCV	\$ 75,881	\$ 78,870	\$ 81,324	\$ 83,820	\$ 86,348
Rota	\$ 49,725	\$ 51,649	\$ 53,227	\$ 54,832	\$ 56,458
YF routine	\$ 40,695	\$ 42,249	\$ 43,523	\$ 44,819	\$ 46,131
<b>Total</b>	<b>\$ 268,022</b>	<b>\$ 268,414</b>	<b>\$ 279,692</b>	<b>\$ 280,815</b>	<b>\$ 289,324</b>

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.
- Projections of measles programme not available.